BioNTech (BNTX) Beat Earnings, But Are Things About To Change?

For a lot of us, the nightmare of the pandemic is slowly starting to fade; life is returning to normal as vaccination numbers rise and restrictions vanish. Various pharmaceutical companies were thrown into the spotlight as they competed in a vaccine race, creating serious market volatility in the process. Now though, as vaccination rates increase, a lot of investors are left thinking that sales for company’s like BioNTech (NASDAQ: BNTX) are about to hit a steep dip – and they might not be wrong. 

Currently, the quarterly report for BioNTech illustrates strong vaccine sales; hinged on the growth of the Omnicron variant earlier this year. But as Omicron starts to fade, the unprecedented revenue rise will give way to a dip back to pre-pandemic revenue patterns. The company’s vaccine – developed with Pfizer – led to a Q1 revenue of $6.4B, more than triple the previous year, and soaring past analyst estimates of $4.6B. Again tripling from the year before, BioNTech’s earnings were pegged at $14.24, significantly higher than the consensus forecast of $9.71. 

Read Also: Best Healthcare Stocks To Buy Right Now

Investors should be focused on one particular potential problem for BioNTech – vaccine oversupply. With various companies now issuing global supplies of Covid-19 vaccines, not only is competition swamped, but demand no longer outweighs supply. BioNTech is well aware of the revenue drop, anticipating between $13B and $17B, compared to $19B the previous year. Health analytics firm Airfinity slashed its global sales forecast for the rest of the year by 20% to $64.1B; with various other big pharma names cutting revenue outlooks on the basis of oversupply. 

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

BioNTech isn’t just a Covid play though, the company has been making promising progress in its potentially breakthrough cancer drugs, as well as pledging around $1.4B for R&D this year. So all in all, whilst revenue is definitely about to dip, there’s potential in the pipeline for BioNTech.